Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief

Biogen Japan President Shinichi Torii (left), Managing Director Ajai Sulekh Despite the aducanumab flop earlier this year and the arrival of a one-time competitor treatment in the spinal muscular atrophy (SMA) space, Biogen Japan helmsman Ajai Sulekh stresses the big...read more